Monoclonal Gammopathy Diagnosis and Management

Introduction to Monoclonal Gammopathies

The International Myeloma Society recommends that a monoclonal gammopathy detected by serum protein electrophoresis requires thorough evaluation, as it may signal a risk of progression to multiple myeloma or other malignant hematological disorders, with specific risk factors identifying the most concerning cases 1, 2

Monoclonal gammopathy of undetermined significance (MGUS) is the most common precancerous condition, with a concentration of monoclonal protein ≥15 g/l, type IgA or IgM, and abnormal free light chain (FLC) ratio being risk factors for progression 1, 3, 4
Smoldering multiple myeloma (SMM) is an intermediate stage between MGUS and symptomatic multiple myeloma, defined by a monoclonal protein ≥30 g/l and/or clonal bone marrow plasma cells ≥10% 2
The presence of risk factors increases the probability of progression to a malignant hematological disorder, with a 20-year risk of progression of 58% with 3 risk factors, 37% with 2 risk factors, 21% with 1 risk factor, and 5% with no risk factors 1, 3

The International Myeloma Society recommends repeating serum protein electrophoresis 3-6 months after initial detection, complete blood count, calcium and creatinine levels, and qualitative test for proteinuria, with further evaluation if proteinuria is present 1, 5
For MGUS with low risk (all criteria), the recommended follow-up is serum protein electrophoresis at 6 months, then every 2-3 years if stable, while MGUS with intermediate or high risk requires more frequent follow-up and additional evaluation, including bone marrow aspiration and biopsy, conventional cytogenetics, and FISH 2, 4

Serum immunofixation electrophoresis (IFE) is more sensitive than simple electrophoresis for detecting monoclonal gammopathies and is essential for confirming monoclonality and determining the type of immunoglobulin 6, 7
Free light chain (FLC) measurement is an independent measure of κ and λ light chains, with an abnormal κ:λ ratio indicating clonality, and a normal ratio value of 0.26-1.65 (which may be modified in case of renal insufficiency) 7

Quantitative immunoglobulin levels (IgG, IgA, IgM) should be measured by nephelometry to confirm and grade the degree of hypogammaglobulinemia. 8
Serum calcium and albumin concentrations should be obtained to assess for end‑organ damage (e.g., hypercalcemia) in patients with low gamma‑globulin. 9

An M‑protein concentration ≥ 15 g/L classifies a patient as high‑risk MGUS. 9
Twenty‑year risk of progression to multiple myeloma varies with the number of risk factors present:
- 3 risk factors → 58 %
- 2 risk factors → 37 %
- 1 risk factor → 21 %
- 0 risk factors → 5 %

For intermediate‑ or high‑risk MGUS (≥ 1 risk factor), repeat serum protein electrophoresis (SPEP) every 3–6 months initially, then at longer intervals if stable. 9
Patients should be monitored for CRAB criteria using the following thresholds:
- Hypercalcemia ≥ 11.5 mg/dL
- Renal insufficiency with serum creatinine ≥ 2 mg/dL
- Anemia with hemoglobin < 10 g/dL or ≥ 2 g/dL below the normal range
- Lytic bone lesions